VBI Vaccines (Nasdaq: VBIV) (“VBI”) is scheduled to present at the Eighth Annual LD Micro Conference on Thursday, December 3rd, 2015 at 1:30 PM ET (10:30 AM PT). The event is being held at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.

During the presentation, Jeff Baxter, VBI’s President and CEO, will provide an overview of VBI and its platform technologies, and will summarize recent developments in the company’s cytomegalovirus (“CMV”), glioblastoma multiforme (“GBM”), and respiratory syncytial virus (“RSV”) vaccine programs.

Mr. Baxter will also discuss VBI’s planned merger with SciVac Therapeutics (TSX:VAC and OTCQX:SVACF) (“SciVac”), including SciVac’s flagship product, Sci-B-Vac®, which is a commercial hepatitis B (“HBV”) vaccine.

“We continue to make great strides in advancing our pipeline of preventative and therapeutic vaccine candidates,” said Mr. Baxter. “We believe that our proposed merger with SciVac would bring a commercial vaccine together with unique vaccine development and manufacturing capabilities. We look forward to potentially combining SciVac’s assets and talent to create what we believe will become a leading global vaccine developer.”

If you would like to schedule a one-on-one meeting with VBI, please contact LD Micro at (408) 457-1042.

Event Details

  • Event: Eighth Annual LD Micro Conference
  • Date: Thursday, December 3rd, 2015
  • Time: 1:30 PM ET (10:30 AM PT)
  • Location: Luxe Sunset Boulevard Hotel in Los Angeles, CA
  • Event Website: http://bit.ly/ldmicro-2015